Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

Takeda Pharmaceuticals, Japan's largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, ...

Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products ... companies to manufacture more in the United States. January 24, 2025 ...

Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data. Gastrointestinal diseases are one of the Japanese ...

Earnings Call Insights: Takeda Pharmaceutical Company Limited (NYSE ... driven by Growth & Launch products, which grew by ...

We have seen 140 institutional investors add shares of TAK stock to their portfolio, and 133 decrease their positions in their most recent quarter. Here are some of the largest recent moves: Wall ...

Drugmakers have said they’re still unclear about whether Trump will impose tariffs on finished products or on ... to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...